XML 46 R36.htm IDEA: XBRL DOCUMENT
v3.21.2

Acquisitions (Asset Acquisitions) (Details) - USD ($) $ in Millions | 1 Months Ended | 3 Months Ended | 6 Months Ended
--- | --- | --- | ---
May 31, 2021 | Mar. 31, 2021 | Jan. 31, 2021 | Jun. 30, 2020 | May 31, 2020 | Mar. 31, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Acquired IPR&D Expense |  |  |  |  |  |  | $ 25.0 | $ 241.8 | $ 324.3 | $ 294.1
Acquired in-process research and development (Note 3) |  |  |  |  |  |  | $ 25.0 | $ 241.8 | $ 324.3 | $ 294.1
Precision Biosciences, Inc. |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Acquired IPR&D Expense |  |  | $ 107.8 |  |  |  |  |  |  |
Merus N.V. |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Acquired IPR&D Expense |  |  | 46.5 |  |  |  |  |  |  |
Asahi Kasei Pharma Corporation |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Acquired IPR&D Expense |  |  | $ 20.0 |  |  |  |  |  |  |
Rigel Pharmaceuticals, Inc. |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Acquired IPR&D Expense |  | $ 125.0 |  |  |  |  |  |  |  |
MiNA Therapeutics Limited |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Acquired IPR&D Expense | $ 25.0 |  |  |  |  |  |  |  |  |
Sitryx Therapeutics Limited |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Acquired IPR&D Expense |  |  |  |  |  | $ 52.3 |  |  |  |
AbCellera Biologics Inc. |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Acquired IPR&D Expense |  |  |  |  | $ 25.0 | $ 25.0 |  |  |  |
Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences) |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Acquired IPR&D Expense |  |  |  |  | 20.0 |  |  |  |  |
Undisclosed |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Acquired IPR&D Expense |  |  |  |  | $ 174.8 |  |  |  |  |
Evox Therapeutics Limited |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Acquired IPR&D Expense |  |  |  | $ 22.0 |  |  |  |  |  |

X
- Definition The amount of EXPENSE related to research and development assets that are acquired in a business combination (pre-141R) and/or licensing arrangement that have no alternative future use and are therefore written off in the period of acquisition (INCOME STATEMENT) + References No definition available. + Details
Name: | lly_AcquiredInProcessResearchAndDevelopment
Namespace Prefix: | lly_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_PrecisionBiosciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_MerusNVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_AsahiKaseiPharmaCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_RigelPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_MiNATherapeuticsLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_SitryxTherapeuticsLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_AbCelleraBiologicsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_JunshiBiosciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_UndisclosedAssetAcquisitionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_EvoxTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |